Close

Stay up to date with FEG

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Markets have been engaged by Zetaris to manage this offer and will receive fees based on the uptake of this offer.

Play icon

Investor Q&A with Steven Yatomi-Clarke

In this session Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke discussed the key highlights:

  • An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
  • The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
  • Why the data from their PTX-100 Phase 1b trial is so promising.
  • How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
  • How their $18m cash position allows them to go deep into a Phase 2 trial.

Recorded on 25th March 2024 at 12pm (AEDT).

Stay up to date with PTX

Company News

View all

Open investments

View all

Xsights

Request Offer Docs

Investment Type:

Equity

Our Role:

Disrupting a $300bn industry which has not seen innovation in decades
Investment Overview

Copper Bay Resources

Request Offer Docs

Investment Type:

Equity

Our Role:

Large-scale, development-ready, copper project with the potential to become a top-10 US producer.
Investment Overview

Upcoming Convertible Notes

Opening soon

Investment Type:

Convertible Note
Register

upcoming events

View all

Request a Call Back
Register to receive more information on our deal flow. To be able to provide you with the deal flow we need to know who you are.

Speak to an Adviser

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.

latest other webcasts

Xsights Investor Briefing

Xsights Q&A with Steve Wildisen

Q&A With John Forwood

Follow PTX

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.